Developer docs
API playgroundTry for free, no card

Search company profiles

Orna Therapeutics

Full company profile

uuid00005dj

Namestring
Orna Therapeutics
Legal namestring
Orna Therapeutics, Inc.
Websiteurl
ornatx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Orna Therapeutics is a clinical-stage biotechnology company that develops engineered circular RNA (oRNA®) therapeutics paired with proprietary lipid nanoparticle (LNP) delivery systems for the treatment of cancer, autoimmune diseases, genetic disorders, and infectious disease. The company's core platform replaces linear mRNA with self-circularized RNA constructs that exhibit greater stability, longer half-life, simplified manufacturing, lower immunogenicity, and higher protein expression via engineered IRES elements. Orna's technology stack is anchored by four interlocking modules: the oRNA® circular RNA platform, non-hepatic LNP formulations, the panCAR™ in vivo CAR delivery platform (which generates CAR-T, CAR-NK, and CAR-Mac cells simultaneously without lymphodepletion or ex vivo manufacturing), and the STEM™ LNP platform for in vivo gene editing in bone marrow. Discovery is supported by the FoRCE™ high-throughput screening platform for oRNA variant optimization.

Orna's lead clinical candidate, ORN-252, is an anti-CD19 in vivo CAR-T therapy targeting B cell-driven autoimmune diseases such as lupus, rheumatoid arthritis, and myasthenia gravis; the company described the program as clinical-trial-ready with an IND/CTA submission planned for 2025 and first-in-human studies anticipated in 2026. Additional pipeline programs include an anti-CD19/anti-BCMA in vivo CAR for B cell malignancies, an in vivo gene editing program for sickle cell disease and beta-thalassemia (through a Vertex collaboration), and an infectious disease vaccine program (through a Merck collaboration). As of the latest available data, Orna had no commercial products and no publicly disclosed product pricing.

Orna has operated a partnership-driven business model rather than building an internal commercial sales force, monetizing its platform through large licensing and collaboration agreements with major pharmaceutical partners (Merck up to $3.75 billion, Vertex up to $4.35 billion, and Simnova Biotherapeutics for the China market). The company raised a $221 million Series B in August 2022 at an implied valuation above $1.5 billion and acquired ReNAgade Therapeutics in May 2024 to add LNP delivery capability in-house. On February 9, 2026, Eli Lilly and Company announced a definitive agreement to acquire Orna for up to $2.4 billion in cash (upfront plus milestone payments), following which Orna operates as a wholly owned subsidiary of Eli Lilly; commercialization of ORN-252 and the broader oRNA platform is expected to occur through Lilly's enterprise infrastructure.

Short descriptiontext

Orna Therapeutics is a clinical-stage biotechnology company developing engineered circular RNA (oRNA®) therapeutics and proprietary non-hepatic LNP delivery for autoimmune, oncology, genetic, and infectious diseases, now operating as a wholly owned subsidiary of Eli Lilly and Company.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
circular RNA therapeutics, lipid nanoparticle delivery, in vivo cell therapy, gene editing delivery, RNA therapeutic platform
Industry1 code
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology licensing and milestone payments
TypeLicensing Royalties
Description

Pre-commercial revenue generated through collaboration agreements with major pharmaceutical partners, including upfront payments, research funding, and milestone-based payments tied to development and commercialization achievements. Example: Vertex collaboration valued up to $4.35B; Merck collaboration valued up to $3.75B with $150M upfront and up to $3.5B in milestones.

visionlifesciences.com
2Venture capital financing
TypeSubscription Recurring
Description

Pre-revenue startup funding via equity rounds, including a $221 million Series B financing in August 2022 led by BioImpact Capital at a Series B valuation over $1.5 billion.

benzinga.com
3Strategic acquisition value (Eli Lilly)
TypeOne Time License
Description

Company acquired by Eli Lilly in February 2026 for up to $2.4 billion in cash (upfront plus milestone payments), transitioning the business into a wholly owned subsidiary model with future value captured through Lilly's commercialization of ORN-252 and the oRNA platform.

finance.yahoo.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1oRNA®
Description

Engineered circular RNA platform developed by Orna, used as the foundation of Orna's therapeutic programs.

ornatx.com
+4 more records
Core offering1 text field

Orna Therapeutics develops engineered circular RNA (oRNA®) therapeutics paired with proprietary lipid nanoparticle (LNP) delivery systems for in vivo cell engineering and gene editing. The platform enables off-the-shelf, redosable treatments for oncology, autoimmune diseases, infectious disease, and genetic blood disorders, with lead candidate ORN-252 (anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases) and partnered programs with Merck (vaccines), Vertex (gene editing for sickle cell disease and beta-thalassemia), and Simnova (oncology/China market).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Robust B cell depletion demonstrated in non-human primate models supporting in vivo panCAR approach
+3 more records
Product overview1 text field

Orna Therapeutics offers a unified circular RNA therapeutics platform composed of multiple interlocking modules: the core oRNA® (engineered circular RNA) technology, novel LNP delivery solutions, the panCAR™ in vivo CAR delivery platform, the STEM™ bone marrow delivery platform, and the FoRCE™ high-throughput screening platform. The pipeline products — led by ORN-252 (anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases) and the anti-CD19 / anti-BCMA in vivo CAR program for B cell malignancies (partnered with Simnova) — are built directly on this oRNA® + LNP platform stack. Additional partnered programs include a gene editing collaboration with Vertex for sickle cell disease and beta thalassemia, and an infectious disease vaccine collaboration with Merck. Since February 2026, Orna has operated as a wholly owned subsidiary of Eli Lilly and Company.

Product and service8 records
1oRNA® (engineered circular RNA)
CategoryCore platform technology
Description

Orna's proprietary engineered circular RNA platform formed by self-circularization from a linear RNA precursor. oRNA offers simplified production (no caps, tails, or modified nucleotides), simple purification with lower immune reaction risk, longer RNA half-life, increased protein expression via IRES function discoveries, larger cargo capacity, and easier formulation into lipid nanoparticles. Sold/licensed to pharma partners as a standalone platform technology.

2panCAR™ in vivo CAR delivery platform
CategoryDelivery platform / in vivo CAR technology
Description

In vivo CAR delivery platform combining oRNA® technology with proprietary LNPs to modify immune cells within a patient without lymphodepletion. Generates CAR-T, CAR-NK, and CAR-Mac cells at once in an off-the-shelf, easily redosable format for oncology and autoimmune indications. Licensed as a standalone platform.

3STEM™ (SiTu Editing in the Marrow)
CategoryDelivery platform
Description

LNP delivery platform targeting stem cells in the bone marrow using passive targeting, enabling potential treatment of certain genetic diseases such as sickle cell disease and beta-thalassemia directly in the bone marrow without requiring ex vivo cell extraction. Licensed as a standalone platform.

4FoRCE™ (Formulated oRNA Cell-based Evaluation)
CategoryHigh-throughput screening platform
Description

High-throughput screening platform that evaluates thousands of oRNA variants in LNPs across multiple cell types to identify optimal sequences with ideal performance; adapts viral expression elements into oRNA constructs to increase potency by orders of magnitude.

5ORN-252
CategoryLead clinical candidate (in vivo CAR-T)
Description

Orna's lead clinical-trial-ready in vivo CAR-T cell therapy targeting CD19, using circular RNA paired with lipid nanoparticles to treat B cell-driven autoimmune diseases such as lupus and rheumatoid arthritis. Demonstrated robust B cell depletion in non-human primate models; Phase 1 clinical trial application anticipated in 2025-2026.

6Anti-CD19 / Anti-BCMA in vivo CAR program (B cell malignancies)
CategoryPipeline program
Description

Pipeline program targeting B cell malignancies (lymphoma, multiple myeloma, leukemia) using an anti-CD19 / anti-BCMA in vivo CAR approach with panCAR™ delivery, partnered with Simnova Biotherapeutics for CAR proteins, rapid early clinical assessment, and China market access.

7Gene editing program (sickle cell disease and beta-thalassemia)
CategoryPipeline program (collaboration)
Description

Collaboration with Vertex Pharmaceuticals leveraging Orna's differentiated LNP delivery solutions and STEM™ bone marrow-targeted platform to support Vertex's efforts in developing next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

8Infectious disease vaccine program
CategoryPipeline program (collaboration)
Description

Collaboration with Merck leveraging the potency and durability of Orna's oRNA® platform coupled with novel LNP delivery insights to develop next-generation vaccine candidates using protective antigens and other strategies, targeting undisclosed antigens with potential application to multiple pathogens.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagship PartnershipTypeStrategic or Co-development PartnerAnnounced on2026-02-09
Description

Eli Lilly acquired Orna Therapeutics for up to $2.4 billion in cash (including upfront and milestone-based payments); the deal provides Lilly with Orna's oRNA platform and lead asset ORN-252 (clinical-trial-ready anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases). Transaction announced February 9, 2026, expected to close in first half of 2026. Orna now operates as a wholly owned subsidiary of Eli Lilly.

Strategic tierFlagship PartnershipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Vertex collaboration (valued up to $4.35 billion) leverages Orna's differentiated LNP delivery solutions to enhance Vertex's efforts in developing next-generation gene editing therapies. Pipeline focuses on sickle cell disease and beta-thalassemia through Orna's STEM™ (SiTu Editing in the Marrow) bone marrow-targeted LNP delivery platform. Pre-existing collaboration that was anticipated to raise antitrust considerations following Lilly's acquisition.

Strategic tierCore PartnershipTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Partnership provides access to CAR proteins, rapid early clinical assessment, and the China market for multiple potential oncology therapies. Targets anti-CD19 / anti-BCMA in vivo CAR for B cell malignancies using Orna's panCAR™ platform. Originated in 2024 alongside Orna's acquisition of ReNAgade Therapeutics.

Strategic tierFlagship PartnershipTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Orna is collaborating with Merck to develop the next generation of vaccine candidates by leveraging the potency and durability of the oRNA® platform with novel LNP delivery insights. The 2022 BioImpact Capital-announced collaboration covering vaccines and cancer treatments was valued up to $3.75 billion with $150 million upfront and up to $3.5 billion in milestones; pipeline page lists 'Infectious disease & others / Protective antigens & other strategies' as the Merck collaboration track.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Laronde Therapeutics (now Sail Biomedicines)
TypeDirect peer
Description

Pioneer in engineered circular RNA therapeutics (eRNA) and a founding competitor in the same modality category as Orna's oRNA® platform, with comparable long-duration, redosable protein expression strategy.

TypeEmerging player
Description

Develops self-replicating and circular RNA-based programmable therapeutics for oncology and other diseases; shares Orna's focus on next-generation RNA constructs and programmable gene expression.

TypeBroad incumbent
Description

Leader in linear mRNA therapeutics and LNP delivery, with deep resources targeting vaccines, oncology, rare diseases, and autoimmune indications — the modality incumbent against which oRNA® competes for share.

TypeBroad incumbent
Description

Established RNA-based therapeutics company (siRNA platform) with deep CMC and LNP manufacturing expertise; Orna's CTO Siva Sakhamuri was previously VP of Manufacturing at Alnylam, and both companies target genetically defined diseases.

TypeBroad incumbent
Description

Flagship Orna collaboration partner (up to $4.35B) and a major player in sickle cell disease/beta-thalassemia via Casgevy (ex vivo gene editing); a comparable counterparty in the gene-editing therapeutic space and potential competitive threat post-Lilly acquisition.

TypeDirect peer
Description

In vivo and ex vivo base editing therapeutics targeting sickle cell disease, beta-thalassemia, and other genetic diseases — directly comparable to Orna's STEM™-enabled in vivo gene editing programs and to the partnered Vertex program.

TypeDirect peer
Description

In vivo base editing for cardiovascular and other genetic diseases using LNP delivery; shares Orna's focus on in vivo delivery (LNP-based) for genetic diseases and competes for the same non-hepatic LNP targeting advances.

TypeBroad incumbent
Description

In vivo CRISPR/Cas9 gene editing platform using LNP delivery for genetic diseases and oncology; directly comparable to Orna's STEM™ platform and in vivo editing ambitions.

TypeBroad incumbent
Description

Global mRNA therapeutics leader with extensive vaccine, oncology, and cell therapy pipelines, plus LNP delivery expertise; the European incumbent against which circular RNA platforms will compete for share.

TypeDirect peer
Description

Clinical-stage CAR-T developer focused on B cell-driven autoimmune diseases (lupus, myositis, etc.) using CD19-directed cell therapy; directly competes with ORN-252 for the same autoimmune patient population and physician audience.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orna Therapeutics

RNA Therapeuticsornatx.com

Orna Therapeutics is a clinical-stage biotechnology company developing engineered circular RNA (oRNA®) therapeutics and proprietary non-hepatic LNP delivery for autoimmune, oncology, genetic, and infectious diseases, now operating as a wholly owned subsidiary of Eli Lilly and Company.

What Orna Therapeutics does

Orna Therapeutics is a clinical-stage biotechnology company that develops engineered circular RNA (oRNA®) therapeutics paired with proprietary lipid nanoparticle (LNP) delivery systems for the treatment of cancer, autoimmune diseases, genetic disorders, and infectious disease. The company's core platform replaces linear mRNA with self-circularized RNA constructs that exhibit greater stability, longer half-life, simplified manufacturing, lower immunogenicity, and higher protein expression via engineered IRES elements. Orna's technology stack is anchored by four interlocking modules: the oRNA® circular RNA platform, non-hepatic LNP formulations, the panCAR™ in vivo CAR delivery platform (which generates CAR-T, CAR-NK, and CAR-Mac cells simultaneously without lymphodepletion or ex vivo manufacturing), and the STEM™ LNP platform for in vivo gene editing in bone marrow. Discovery is supported by the FoRCE™ high-throughput screening platform for oRNA variant optimization.

Orna's lead clinical candidate, ORN-252, is an anti-CD19 in vivo CAR-T therapy targeting B cell-driven autoimmune diseases such as lupus, rheumatoid arthritis, and myasthenia gravis; the company described the program as clinical-trial-ready with an IND/CTA submission planned for 2025 and first-in-human studies anticipated in 2026. Additional pipeline programs include an anti-CD19/anti-BCMA in vivo CAR for B cell malignancies, an in vivo gene editing program for sickle cell disease and beta-thalassemia (through a Vertex collaboration), and an infectious disease vaccine program (through a Merck collaboration). As of the latest available data, Orna had no commercial products and no publicly disclosed product pricing.

Orna has operated a partnership-driven business model rather than building an internal commercial sales force, monetizing its platform through large licensing and collaboration agreements with major pharmaceutical partners (Merck up to $3.75 billion, Vertex up to $4.35 billion, and Simnova Biotherapeutics for the China market). The company raised a $221 million Series B in August 2022 at an implied valuation above $1.5 billion and acquired ReNAgade Therapeutics in May 2024 to add LNP delivery capability in-house. On February 9, 2026, Eli Lilly and Company announced a definitive agreement to acquire Orna for up to $2.4 billion in cash (upfront plus milestone payments), following which Orna operates as a wholly owned subsidiary of Eli Lilly; commercialization of ORN-252 and the broader oRNA platform is expected to occur through Lilly's enterprise infrastructure.

Orna Therapeutics firmographics

Firmographics
Name
Orna Therapeutics
Legal name
Orna Therapeutics, Inc.
Website
https://ornatx.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
101–250 employees
Short description
Orna Therapeutics is a clinical-stage biotechnology company developing engineered circular RNA (oRNA®) therapeutics and proprietary non-hepatic LNP delivery for autoimmune, oncology, genetic, and infectious diseases, now operating as a wholly owned subsidiary of Eli Lilly and Company.
Ownership category
akta.pro rank

Orna Therapeutics industry classification

Industry
Product category
RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Circular RNA therapeutics
  • Lipid nanoparticle delivery
  • In vivo cell therapy
  • Gene editing delivery
  • RNA therapeutic platform

Where Orna Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Orna Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Technology licensing and milestone payments: Pre-commercial revenue generated through collaboration agreements with major pharmaceutical partners, including upfront payments, research funding, and milestone-based payments tied to development and commercialization achievements. Example: Vertex collaboration valued up to $4.35B; Merck collaboration valued up to $3.75B with $150M upfront and up to $3.5B in milestones.
  2. Venture capital financing: Pre-revenue startup funding via equity rounds, including a $221 million Series B financing in August 2022 led by BioImpact Capital at a Series B valuation over $1.5 billion.
  3. Strategic acquisition value (Eli Lilly): Company acquired by Eli Lilly in February 2026 for up to $2.4 billion in cash (upfront plus milestone payments), transitioning the business into a wholly owned subsidiary model with future value captured through Lilly's commercialization of ORN-252 and the oRNA platform.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Orna Therapeutics product offering

Product offering

Core offering

Orna Therapeutics develops engineered circular RNA (oRNA®) therapeutics paired with proprietary lipid nanoparticle (LNP) delivery systems for in vivo cell engineering and gene editing. The platform enables off-the-shelf, redosable treatments for oncology, autoimmune diseases, infectious disease, and genetic blood disorders, with lead candidate ORN-252 (anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases) and partnered programs with Merck (vaccines), Vertex (gene editing for sickle cell disease and beta-thalassemia), and Simnova (oncology/China market).

Product overview

Orna Therapeutics offers a unified circular RNA therapeutics platform composed of multiple interlocking modules: the core oRNA® (engineered circular RNA) technology, novel LNP delivery solutions, the panCAR™ in vivo CAR delivery platform, the STEM™ bone marrow delivery platform, and the FoRCE™ high-throughput screening platform. The pipeline products — led by ORN-252 (anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases) and the anti-CD19 / anti-BCMA in vivo CAR program for B cell malignancies (partnered with Simnova) — are built directly on this oRNA® + LNP platform stack. Additional partnered programs include a gene editing collaboration with Vertex for sickle cell disease and beta thalassemia, and an infectious disease vaccine collaboration with Merck. Since February 2026, Orna has operated as a wholly owned subsidiary of Eli Lilly and Company.

Differentiator

Problem solved

Functional benefit

Brands

  • oRNA®: Engineered circular RNA platform developed by Orna, used as the foundation of Orna's therapeutic programs.
  • panCAR™
  • FoRCE™ (Formulated oRNA Cell-based Evaluation)
  • SiTu Editing in the Marrow (STEM)™
  • OROBOROS

Products and services

  • oRNA® (engineered circular RNA) Orna's proprietary engineered circular RNA platform formed by self-circularization from a linear RNA precursor. oRNA offers simplified production (no caps, tails, or modified nucleotides), simple purification with lower immune reaction risk, longer RNA half-life, increased protein expression via IRES function discoveries, larger cargo capacity, and easier formulation into lipid nanoparticles. Sold/licensed to pharma partners as a standalone platform technology.
  • panCAR™ in vivo CAR delivery platform In vivo CAR delivery platform combining oRNA® technology with proprietary LNPs to modify immune cells within a patient without lymphodepletion. Generates CAR-T, CAR-NK, and CAR-Mac cells at once in an off-the-shelf, easily redosable format for oncology and autoimmune indications. Licensed as a standalone platform.
  • STEM™ (SiTu Editing in the Marrow) LNP delivery platform targeting stem cells in the bone marrow using passive targeting, enabling potential treatment of certain genetic diseases such as sickle cell disease and beta-thalassemia directly in the bone marrow without requiring ex vivo cell extraction. Licensed as a standalone platform.
  • FoRCE™ (Formulated oRNA Cell-based Evaluation) High-throughput screening platform that evaluates thousands of oRNA variants in LNPs across multiple cell types to identify optimal sequences with ideal performance; adapts viral expression elements into oRNA constructs to increase potency by orders of magnitude.
  • ORN-252 Orna's lead clinical-trial-ready in vivo CAR-T cell therapy targeting CD19, using circular RNA paired with lipid nanoparticles to treat B cell-driven autoimmune diseases such as lupus and rheumatoid arthritis. Demonstrated robust B cell depletion in non-human primate models; Phase 1 clinical trial application anticipated in 2025-2026.
  • Anti-CD19 / Anti-BCMA in vivo CAR program (B cell malignancies) Pipeline program targeting B cell malignancies (lymphoma, multiple myeloma, leukemia) using an anti-CD19 / anti-BCMA in vivo CAR approach with panCAR™ delivery, partnered with Simnova Biotherapeutics for CAR proteins, rapid early clinical assessment, and China market access.
  • Gene editing program (sickle cell disease and beta-thalassemia) Collaboration with Vertex Pharmaceuticals leveraging Orna's differentiated LNP delivery solutions and STEM™ bone marrow-targeted platform to support Vertex's efforts in developing next-generation gene editing therapies for sickle cell disease and beta-thalassemia.
  • Infectious disease vaccine program Collaboration with Merck leveraging the potency and durability of Orna's oRNA® platform coupled with novel LNP delivery insights to develop next-generation vaccine candidates using protective antigens and other strategies, targeting undisclosed antigens with potential application to multiple pathogens.

Quantifiable outcome

  • Robust B cell depletion demonstrated in non-human primate models supporting in vivo panCAR approach
  • +3 more outcomes

Companies that use Orna Therapeutics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Orna Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Orna Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship partnership and core partnership.

  • Eli Lilly and Companyflagship partnershipStrategic or Co-development Partner · 9 February 2026Eli Lilly acquired Orna Therapeutics for up to $2.4 billion in cash (including upfront and milestone-based payments); the deal provides Lilly with Orna's oRNA platform and lead asset ORN-252 (clinical-trial-ready anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases). Transaction announced February 9, 2026, expected to close in first half of 2026. Orna now operates as a wholly owned subsidiary of Eli Lilly.
  • Vertex Pharmaceuticalsflagship partnershipStrategic or Co-development Partner · 1 January 2025Vertex collaboration (valued up to $4.35 billion) leverages Orna's differentiated LNP delivery solutions to enhance Vertex's efforts in developing next-generation gene editing therapies. Pipeline focuses on sickle cell disease and beta-thalassemia through Orna's STEM™ (SiTu Editing in the Marrow) bone marrow-targeted LNP delivery platform. Pre-existing collaboration that was anticipated to raise antitrust considerations following Lilly's acquisition.
  • Simnova Biotherapeuticscore partnershipStrategic or Co-development Partner · 1 May 2024Partnership provides access to CAR proteins, rapid early clinical assessment, and the China market for multiple potential oncology therapies. Targets anti-CD19 / anti-BCMA in vivo CAR for B cell malignancies using Orna's panCAR™ platform. Originated in 2024 alongside Orna's acquisition of ReNAgade Therapeutics.
  • Merck & Co.flagship partnershipStrategic or Co-development Partner · 1 August 2022Orna is collaborating with Merck to develop the next generation of vaccine candidates by leveraging the potency and durability of the oRNA® platform with novel LNP delivery insights. The 2022 BioImpact Capital-announced collaboration covering vaccines and cancer treatments was valued up to $3.75 billion with $150 million upfront and up to $3.5 billion in milestones; pipeline page lists 'Infectious disease & others / Protective antigens & other strategies' as the Merck collaboration track.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Orna Therapeutics competitors and assessment

Company assessment

Direct peers

  • Laronde Therapeutics (now Sail Biomedicines): Pioneer in engineered circular RNA therapeutics (eRNA) and a founding competitor in the same modality category as Orna's oRNA® platform, with comparable long-duration, redosable protein expression strategy.
  • Beam Therapeutics: In vivo and ex vivo base editing therapeutics targeting sickle cell disease, beta-thalassemia, and other genetic diseases — directly comparable to Orna's STEM™-enabled in vivo gene editing programs and to the partnered Vertex program.
  • Verve Therapeutics: In vivo base editing for cardiovascular and other genetic diseases using LNP delivery; shares Orna's focus on in vivo delivery (LNP-based) for genetic diseases and competes for the same non-hepatic LNP targeting advances.
  • Cabaletta Bio: Clinical-stage CAR-T developer focused on B cell-driven autoimmune diseases (lupus, myositis, etc.) using CD19-directed cell therapy; directly competes with ORN-252 for the same autoimmune patient population and physician audience.

Emerging players

  • Strand Therapeutics: Develops self-replicating and circular RNA-based programmable therapeutics for oncology and other diseases; shares Orna's focus on next-generation RNA constructs and programmable gene expression.

Broad incumbents

  • Moderna: Leader in linear mRNA therapeutics and LNP delivery, with deep resources targeting vaccines, oncology, rare diseases, and autoimmune indications — the modality incumbent against which oRNA® competes for share.
  • Alnylam Pharmaceuticals: Established RNA-based therapeutics company (siRNA platform) with deep CMC and LNP manufacturing expertise; Orna's CTO Siva Sakhamuri was previously VP of Manufacturing at Alnylam, and both companies target genetically defined diseases.
  • Vertex Pharmaceuticals: Flagship Orna collaboration partner (up to $4.35B) and a major player in sickle cell disease/beta-thalassemia via Casgevy (ex vivo gene editing); a comparable counterparty in the gene-editing therapeutic space and potential competitive threat post-Lilly acquisition.
  • Intellia Therapeutics: In vivo CRISPR/Cas9 gene editing platform using LNP delivery for genetic diseases and oncology; directly comparable to Orna's STEM™ platform and in vivo editing ambitions.
  • BioNTech: Global mRNA therapeutics leader with extensive vaccine, oncology, and cell therapy pipelines, plus LNP delivery expertise; the European incumbent against which circular RNA platforms will compete for share.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Orna Therapeutics social profiles

Digital presence

Orna Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orna Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Orna Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Orna Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orna Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orna Therapeutics

What does Orna Therapeutics do?

Orna Therapeutics develops engineered circular RNA (oRNA®) therapeutics paired with proprietary lipid nanoparticle (LNP) delivery systems for in vivo cell engineering and gene editing. The platform enables off-the-shelf, redosable treatments for oncology, autoimmune diseases, infectious disease, and genetic blood disorders, with lead candidate ORN-252 (anti-CD19 in vivo CAR-T for B cell-driven autoimmune diseases) and partnered programs with Merck (vaccines), Vertex (gene editing for sickle cell disease and beta-thalassemia), and Simnova (oncology/China market).

Is Orna Therapeutics a public or private company?

Orna Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Orna Therapeutics founded?

Orna Therapeutics was founded in 2019. It employs 101 to 250 people.

Where is Orna Therapeutics based?

Orna Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Orna Therapeutics make money?

Three revenue lines are on record. Technology licensing and milestone payments are the primary driver. The others are venture capital financing and strategic acquisition value (Eli Lilly).

Who are Orna Therapeutics's main competitors?

Direct peers on record are Laronde Therapeutics (now Sail Biomedicines), Beam Therapeutics, Verve Therapeutics and Cabaletta Bio. Strand Therapeutics is listed as an emerging player. Broad incumbents are Moderna, Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Intellia Therapeutics and BioNTech.

Does Orna Therapeutics have an API?

No public API is recorded for Orna Therapeutics.

What industry is Orna Therapeutics in?

Orna Therapeutics's product category is RNA Therapeutics. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Phirda超 30 亿美元!2026 年上半年 CAR-T 销售额出炉In H1 2026, five CAR-T drugs generated over $3 billion, with Carvykti leading at $1.254 billion. The market is shifting toward autoimmunity and in vivo CAR-T, with major players acquiring assets. Competition will focus on manufacturing capacity and next-generation platforms.Tech TimesLilly Stock Rises on Alzheimer Deal: Retatrutide Moat Still Not Fully PricedEli Lilly shares rose 3.6% after completing an Alzheimer's drug acquisition and an ion channel collaboration. The company reported Q2 revenue of $22.97 billion, up 48% year-over-year, and raised its full-year guidance to $85–87 billion. Retatrutide's Phase 3 trial showed 28.3% weight loss, with a BLA planned for Q1 2027.GenengnewsStockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue MissEli Lilly reported Q2 2026 earnings that significantly beat analyst expectations, with revenue jumping 48% year-over-year to $22.974 billion and EPS growing 26% to $7.94, prompting the company to raise its 2026 GAAP revenue guidance to $85–87 billion. The strong performance was driven by its GLP-1/GIP drugs Mounjaro ($9.943 billion, up 91%) and Zepbound ($4.928 billion, up 46%), while the company completed $2.4 billion acquisition of Orna Therapeutics and up-to-$2.3 billion buyout of Ajax Therapeutics. Lilly shares rose 6.3% for the week as analysts raised price targets, citing tremendous operating leverage and robust demand for its obesity and diabetes franchises.BiggoLu Gao: Western Pharma’s Circular RNA Blind Spot Will Look Like a $7 Billion Mistake — BigGo FinanceTherona CEO Lu Gao argues that Western pharmaceutical companies are overlooking the circular RNA capabilities of Chinese biotech firm Therona due to communication gaps and awareness issues, despite the company having three clinical programs in human trials. The article highlights Therona's proprietary splint-free enzymatic circularization chemistry and its lead asset TI000032, an in-vivo CAR T therapy for autoimmune diseases, as distinct from competitors like Orna Therapeutics. Therona plans parallel IND filings in the US and China in Q4 2026 and is actively seeking licensing partnerships rather than acquisitions.pharmaphorumLilly's GLP-1s race away in Q2, though Foundayo falls shortEli Lilly reported Q2 revenue of $23 billion, up 48% year-over-year, with Mounjaro and Zepbound growing 91% and 46% respectively. Foundayo, its oral GLP-1, brought in $98 million, below forecasts, while Novo Nordisk's Wegovy pill made nearly $500 million. Lilly also announced eight acquisitions worth over $26 billion and raised its full-year revenue guidance to $85–87 billion.BioSpaceLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressEli Lilly reported Q2 2026 revenue of $23.0 billion, up 48% year-over-year, and EPS of $7.94 reported and $8.38 non-GAAP. The company raised its full-year 2026 revenue guidance to $85–87 billion and EPS guidance to $35.50–36.50, citing strong Mounjaro and Zepbound volume growth.The Motley FoolWhy Eli Lilly Stock Climbed TodayEli Lilly shares rose on Wednesday after the company reported a 48% year-over-year revenue increase to $23 billion in Q2, with obesity drugs Mounjaro and Zepbound driving sales. The company raised its full-year revenue target to $85–87 billion, citing strong pipeline and new assets.PR NewswireLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressEli Lilly reported Q2 2026 revenue of $23.0 billion, up 48% year-over-year, and EPS of $7.94 reported and $8.38 non-GAAP. The company raised its full-year 2026 revenue guidance to $85–87 billion and EPS guidance to $35.50–36.50. It also highlighted regulatory approvals and pipeline progress, including retatrutide's complete clinical data package.TheStreet.comJim Cramer says one popular stock is meant to be owned, not tradedJim Cramer said Eli Lilly is a company to own, not trade, citing its GLP-1 franchise and strong growth. Q1 2026 revenue hit $19.8 billion, up 56% year over year, with full-year guidance raised to $82–85 billion. Q2 earnings on Aug. 5 are expected to show deceleration from Q1's pace.Tech TimesIn Vivo CAR-T’s Liver Problem Now Has Targeted Answer: CREATE Acquires Monash’s 8-Fold LNP FixCREATE Medicines acquired an exclusive license to Monash University's antibody-capture system for lipid nanoparticles, which boosts mRNA delivery to target cells eightfold. The deal supports CREATE's first-in-human Phase 1/2 trial of CRT-402 for autoimmune diseases, approved in Australia. The collaboration aims to expand targeting for solid tumors.